Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Sesen Bio (SESN)

Sesen Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SESN
DateTimeSourceHeadlineSymbolCompany
10/08/202312:30PR Newswire (US)Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:SESNSesen Bio Inc
06/03/202317:41Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
06/03/202317:35Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SESNSesen Bio Inc
03/03/202316:07Edgar (US Regulatory)Sec Staff Action/letter (sec Staff)NASDAQ:SESNSesen Bio Inc
03/03/202316:06Edgar (US Regulatory)Sec Staff Action/letter (sec Staff)NASDAQ:SESNSesen Bio Inc
02/03/202317:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SESNSesen Bio Inc
02/03/202316:32Business WireSesen Bio Stockholders Approve Merger with Carisma TherapeuticsNASDAQ:SESNSesen Bio Inc
28/02/202313:08Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
28/02/202313:03Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SESNSesen Bio Inc
28/02/202313:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SESNSesen Bio Inc
28/02/202313:00Business WireSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsNASDAQ:SESNSesen Bio Inc
27/02/202321:33Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
27/02/202313:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SESNSesen Bio Inc
21/02/202314:05Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
21/02/202314:00Business WireLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With CarismaNASDAQ:SESNSesen Bio Inc
17/02/202313:18Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
17/02/202313:08Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
17/02/202313:04Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
17/02/202313:02Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
16/02/202322:06Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:SESNSesen Bio Inc
16/02/202321:46Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
16/02/202321:42Business WireLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special MeetingNASDAQ:SESNSesen Bio Inc
16/02/202313:02Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
16/02/202313:00Business WireSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerNASDAQ:SESNSesen Bio Inc
15/02/202321:55Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SESNSesen Bio Inc
15/02/202313:02Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
15/02/202313:00Business WireBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsNASDAQ:SESNSesen Bio Inc
14/02/202321:40Edgar (US Regulatory)Registration Pursuant to Securities Act Rule 462(b) of up to an Additional 20% of Securities for an Offering That Was Registered on a Form S-4 (s-4mef)NASDAQ:SESNSesen Bio Inc
14/02/202314:08Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
14/02/202313:00Business WireSesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending MergerNASDAQ:SESNSesen Bio Inc
 Showing the most relevant articles for your search:NASDAQ:SESN